Clarivate PLC: Q3 2025 Financial Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Clarivate PLC is a global provider of transformative intelligence serving the Academia & Government (A&G), Intellectual Property (IP), and Life Sciences & Healthcare (LS&H) markets. The company operates primarily through subscription-based and re-occurring revenue models.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenues | $623.1M | $622.2M | $1,838.2M | $1,893.7M |
| Net Income (Loss) | $(28.3M) | $(65.6M) | $(204.2M) | $(444.9M) |
| Adjusted EBITDA | $252.4M | $264.4M | $747.2M | $775.1M |
| Adjusted EBITDA Margin | 40.5% | 42.5% | 40.6% | 40.9% |
| Operating Cash Flow (YTD) | $468.6M (vs. $505.3M YTD 2024) | |||
| Free Cash Flow (YTD) | $276.1M (vs. $298.4M YTD 2024) | |||
| Total Debt Outstanding | $4,470.2M (Carrying Value: $4,419.0M) | |||
| Cash and Equivalents | $318.7M |
Material Changes vs. Prior Period
- Revenue Stability: Q3 2025 revenue remained flat year-over-year (+0.1%), driven by organic growth in the A&G segment offset by declines in IP and LS&H due to product wind-downs and the ScholarOne divestiture.
- Profitability Improvement: Net loss narrowed significantly to $(28.3M) from $(65.6M) in Q3 2024. This improvement is largely due to the absence of the $316.6M goodwill impairment recorded in the prior year.
- Restructuring Costs: Restructuring charges increased to $11.9M in Q3 2025 (vs. $4.0M in Q3 2024) as the company executes its "Value Creation Plan," primarily involving workforce reductions.
- Debt Refinancing: The company redeemed $600M of Senior Secured Notes due 2026 during the first nine months of 2025, funded by a new $500M term loan tranche and cash on hand.
Outlook, Risks, and Management Commentary
- Strategic Initiatives: Management is executing a "Value Creation Plan" approved in late 2024 to optimize the business model. The company expects to incur approximately $5M in additional restructuring costs in 2025.
- Portfolio Optimization: The company is winding down three product groups within LS&H and A&G segments, expected to reduce revenues and profit by less than 10% and 5%, respectively. The ScholarOne divestiture was completed in November 2024.
- Key Metrics: Annualized Contract Value (ACV) declined 3.4% to $1,542.7M, primarily due to divestitures and wind-downs, though organic ACV grew 1.6%. The annual renewal rate improved to 93% for the nine months ended September 30, 2025.
- Risks: Key risks include dependence on third-party data, competition from free information sources, macroeconomic conditions affecting government and research funding, and cybersecurity threats. Legal proceedings regarding prior accounting restatements remain pending.
Investor Verification Checklist
- Restructuring Execution: Verify the timeline and cost realization of the "Value Creation Plan" to ensure projected savings materialize.
- Organic Growth Sustainability: Assess whether organic revenue growth in the A&G segment can offset the revenue loss from the ScholarOne divestiture and ongoing product wind-downs.
- Debt Service Capacity: Confirm that Free Cash Flow remains sufficient to service the $4.4B debt load, particularly given the refinancing of fixed-rate notes into variable-rate term loans.
- Legal Contingencies: Monitor the status of the securities class action lawsuits regarding prior financial reporting errors and internal controls.
- Share Repurchases: Track the utilization of the remaining $350.5M share repurchase authorization and its impact on earnings per share.